High Levels of Platelet-Lymphocyte Complexes in Patients with Psoriasis Are Associated with a Better Response to Anti–TNF-α Therapy

• Published in: Journal of investigative dermatology Vol. 140; no. 6; pp. 1176 - 1183
• Main Authors: Sanz-Martínez, María Teresa, Moga, Esther, Sánchez Martínez, Miguel Angel, Zamora Atenza, Carlos, Vidal, Silvia, Juárez, Cándido, Puig, Lluís
• Format: Journal Article
• Language: English
• Published: United States Elsevier Inc 01.06.2020
• Subjects: Adalimumab - pharmacology; Adalimumab - therapeutic use; Adult; Anti-Inflammatory Agents - pharmacology; Anti-Inflammatory Agents - therapeutic use; Blood Platelets - immunology; Blood Platelets - metabolism; Female; Humans; Interleukin-17 - metabolism; Male; Middle Aged; Platelet Activation - drug effects; Prognosis; Psoriasis - blood; Psoriasis - drug therapy; Psoriasis - immunology; T-Lymphocytes, Helper-Inducer - immunology; T-Lymphocytes, Helper-Inducer - metabolism; Treatment Outcome; Tumor Necrosis Factor-alpha - antagonists & inhibitors; Tumor Necrosis Factor-alpha - metabolism; PASI; PLyC; pT; PLC; Treg; PBMC; Pso; n.s; Th; TNF-α; W; iGMFI; HD
• ISSN: 0022-202X; 1523-1747; 1523-1747
• DOI: 10.1016/j.jid.2019.08.457

Psoriasis is currently considered to be an immune-mediated disease whose patho-mechanisms involve platelet activation, which seems to correlate with the activity of the disease. Platelet activation is associated with the formation of platelet-lymphocyte complexes (PLyC), although their significance remains unknown. Moreover, biological treatments that target tumor necrosis factor-α (TNF-α) reduce platelet activation. To clarify the significance of PLyC, we compared their levels in patients with psoriasis with those of healthy donors and determined whether platelet binding modifies the secretion of IL-17A by T helper cells. Finally, we assessed the effect of anti–TNF-α treatment on PLyC in responder and non-responder patients with psoriasis. Ours results demonstrated an increase in PLyC in patients with psoriasis. Moreover, the percentage of IL-17-secreting cells was observed to be higher in the platelet-lymphocyte complex population, and these cells tended to secrete greater amounts of IL-17A. Psoriasis patients treated with anti–TNF-α normalized platelet-lymphocyte complex values, and the basal percentage of platelet-T helper lymphocyte complexes was significantly higher in the responder group. In conclusion, PLyC are increased in psoriasis patients, and the number of complexes decreases in response to anti–TNF-α treatment, specifically in the responder group of patients. This finding suggests that PLyC are a prognostic biomarker of response to anti–TNF-α therapy, but prospective studies are necessary to verify these results in patients with psoriasis.